Considering several ongoing clinical trials [37] and the recently FDA-approved drug sacituzumab govitecan-hziy, which combines a TROP2-directed antibody and a topoisomerase inhibitor [38, 39], TROP2 holds promise as a marker for tumor aggressiveness in CRC patients. Here, TACSTD2 is linked to neoplasm.